These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16319226)

  • 21. Longevity bias in cost-effectiveness analysis.
    Liu L; Rettenmaier AJ; Saving TR
    Health Econ; 2008 Apr; 17(4):523-34. PubMed ID: 17990284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valuing reduced antibiotic use for pediatric acute otitis media.
    Meropol SB
    Pediatrics; 2008 Apr; 121(4):669-73. PubMed ID: 18381529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QALYs: the basics.
    Weinstein MC; Torrance G; McGuire A
    Value Health; 2009 Mar; 12 Suppl 1():S5-9. PubMed ID: 19250132
    [No Abstract]   [Full Text] [Related]  

  • 24. CEA is not a price control.
    Cohen J
    Health Aff (Millwood); 2007; 26(5):1505; author reply 1506-7. PubMed ID: 17848464
    [No Abstract]   [Full Text] [Related]  

  • 25. [The cost per year of life gained: trends and internal contradictions].
    van Dam J
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):895; author reply 895. PubMed ID: 17472124
    [No Abstract]   [Full Text] [Related]  

  • 26. Wide variations in the cost-effectiveness of critical care.
    Rosenberg AL; Tremper KK
    Crit Care Med; 2006 Nov; 34(11):2849-51. PubMed ID: 17053572
    [No Abstract]   [Full Text] [Related]  

  • 27. Does technological enhancement of human traits threaten human equality and democracy?
    Shapiro MH
    San Diego Law Rev; 2002; 39(3):769-842. PubMed ID: 15508233
    [No Abstract]   [Full Text] [Related]  

  • 28. The development of new allocation policy for deceased donor kidneys.
    Shapiro ME
    Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):512-5. PubMed ID: 18089963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What affects the quality of economic analysis for life-saving investments?
    Hahn RW; Kosec K; Neumann PJ; Wallsten S
    Risk Anal; 2006 Jun; 26(3):641-55. PubMed ID: 16834624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation.
    Drummond MF; Aguiar-Ibanez R; Nixon J
    Singapore Med J; 2006 Jun; 47(6):456-61; quiz 462. PubMed ID: 16752012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allocating deceased donor kidneys: maximizing years of life.
    Danovitch GM; Bunnapradist S
    Am J Kidney Dis; 2007 Feb; 49(2):180-2. PubMed ID: 17261419
    [No Abstract]   [Full Text] [Related]  

  • 32. Technology assessment in the German context.
    Drummond M
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
    [No Abstract]   [Full Text] [Related]  

  • 33. 'Is there a case for using visual analogue scale valuations in CUA' by Parkin and Devlin. A response: 'yes there is a case, but what does it add to ordinal data?'.
    Brazier J; McCabe C
    Health Econ; 2007 Jun; 16(6):645-7; discussion 649-51. PubMed ID: 17535007
    [No Abstract]   [Full Text] [Related]  

  • 34. Respect for life and the search for the quality of life in medicine: ethical aspects.
    Sgreccia E
    Dolentium Hominum; 1995; 10(1):154-60. PubMed ID: 15839018
    [No Abstract]   [Full Text] [Related]  

  • 35. Searching for El Dorado: the impossibility of finding the right rate.
    Frohlich N; Roos NP
    CMAJ; 2002 Oct; 167(8):880-1. PubMed ID: 12406947
    [No Abstract]   [Full Text] [Related]  

  • 36. Economics and public health: engaged to be happily married!
    Brouwer W; Van Exel J; Van Baal P; Polder J
    Eur J Public Health; 2007 Apr; 17(2):122-3. PubMed ID: 16963790
    [No Abstract]   [Full Text] [Related]  

  • 37. The Quality Adjusted Life Year: A Total-Utility Perspective.
    Firth SJ
    Camb Q Healthc Ethics; 2018 Apr; 27(2):284-294. PubMed ID: 29509126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of quality-adjusted life-years in cost-effectiveness studies.
    Sculpher M
    Allergy; 2006 May; 61(5):527-30. PubMed ID: 16629779
    [No Abstract]   [Full Text] [Related]  

  • 39. Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations?
    Honkanen LA; Mushlin AI; Lachs M; Schackman BR
    J Am Geriatr Soc; 2006 Nov; 54(11):1658-65. PubMed ID: 17087691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An unadjusted NNT was a moderately good predictor of health benefit.
    Chong CA; Tomlinson G; Chodirker L; Figdor N; Uster M; Naglie G; Krahn MD
    J Clin Epidemiol; 2006 Mar; 59(3):224-33. PubMed ID: 16488352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.